Crohn's Disease
Also known as: Crohn Disease, Regional Enteritis, Granulomatous Colitis
Crohn's disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to anus, though it most commonly involves the end of the small intestine (ileum) and beginning of the colon. The inflammation extends through all layers of the bowel wall and can lead to complications such as strictures, fistulas, and abscesses. While there is no cure, treatment can effectively manage symptoms and maintain remission.
Last updated November 10, 2026
Understanding Crohn's Disease
Crohn's disease is one of the two main forms of inflammatory bowel disease: a lifelong condition in which the immune system drives patchy, full-thickness inflammation anywhere from mouth to anus, most often in the last stretch of the small intestine and the first part of the colon. It affects roughly 0.3 percent of adults in North America and Europe. The CDC estimates about 3 million US adults live with IBD, and Crohn's accounts for close to half of them. Onset peaks between ages 15 and 35, with a smaller second peak after 50, and it is slightly more common in women. A first-degree relative with IBD raises risk five- to tenfold, and more than 200 gene variants have been linked to it, NOD2 the best known. Genes are only part of it; incidence is climbing fastest in newly industrialized countries, pointing to diet, antibiotics and the gut microbiome.
A healthy intestinal lining tolerates trillions of bacteria. In Crohn's, a leaky barrier, a less diverse microbiome and an overactive T-helper response (Th1 and Th17 cells pumping out TNF-alpha, interleukin-12 and interleukin-23) combine so that the immune system attacks the bowel wall itself. Because the inflammation runs through every layer, it heals with scar tissue that narrows the bowel (strictures) or tunnels through it (fistulas and abscesses). The disease relapses and remits but tends to progress: within ten years of diagnosis about half of patients have developed a stricture or a penetrating complication, and historically 60 to 70 percent needed surgery at some point. Symptoms are an unreliable guide to what is happening inside. A person can feel well while ulcers deepen, which is why modern care tracks inflammation directly with a blood CRP and a stool calprotectin instead of waiting for pain to return.
The last decade has turned Crohn's from a disease managed by chasing symptoms into one managed by targets. The STRIDE-II consensus (2021) sets the goals as a normal CRP and fecal calprotectin and, ultimately, a healed bowel lining on colonoscopy, not just feeling better. In the CALM trial (2017, 244 patients), adjusting adalimumab to calprotectin and CRP rather than symptoms alone raised mucosal healing at 48 weeks from 30 to 46 percent. Drug choice follows the American College of Gastroenterology (2018) and AGA (2021) guidelines: budesonide or a short prednisone course to settle a flare, never as maintenance, and mesalamine, despite its popularity, does not work for Crohn's. For moderate to severe disease, anti-TNF biologics (infliximab, adalimumab), vedolizumab, ustekinumab, risankizumab and the oral JAK inhibitor upadacitinib each induce remission in roughly 40 to 60 percent. SONIC (2010) found infliximab plus azathioprine gave steroid-free remission in 57 percent versus 30 percent with azathioprine alone, and PROFILE (2024, 386 newly diagnosed patients) found that starting a biologic at diagnosis produced sustained steroid-free remission in 79 percent versus 15 percent with step-up care.
The honest ranking of natural approaches starts with nutrition therapy. Exclusive enteral nutrition, a liquid formula as the only food for six to eight weeks, induces remission in about 80 percent of children, matches corticosteroids in Cochrane's pooled analysis and heals the lining more often than steroids do; it is the first-line induction treatment in pediatric guidelines. The Crohn's Disease Exclusion Diet, a whole-food diet paired with partial formula, kept 76 percent of children in remission at 12 weeks versus 45 percent on EEN alone, and early adult data are positive. Correcting vitamin D, iron, B12 and zinc deficiency is standard care. Beyond that the evidence thins out fast. Curcumin has one small positive induction trial and one failed postoperative trial. Omega-3 fish oil was tested in the two largest supplement trials ever run in Crohn's (EPIC-1 and EPIC-2, 738 patients) and did nothing to prevent relapse. Lactobacillus probiotics failed three maintenance trials and boswellia failed its maintenance trial.
The most common mistake is treating Crohn's as a symptom problem: stopping a biologic because you feel well, reaching for ibuprofen for the aches, or continuing to smoke. Stopping maintenance therapy in remission leads to relapse in roughly half of people within a year, and restarting does not always work as well. NSAIDs trigger flares; use acetaminophen instead. Smoking is the single biggest lever you control: smokers develop Crohn's at about twice the rate of non-smokers, flare more often, need more steroids and surgery, and have double the recurrence after an operation. In a French cohort that followed 474 smokers with Crohn's, those who quit for more than a year had flare rates that fell to the level of never-smokers and needed fewer steroids and immunosuppressants.
At a Glance
- Common symptoms
- Chronic diarrhea, often bloody, Abdominal pain and cramping, Fatigue and malaise
- Main treatments
- Aminosalicylates (mesalamine) for mild disease, Corticosteroids (prednisone, budesonide) for flares, Immunomodulators (azathioprine, methotrexate) for maintenance
- Category
- Autoimmune · Affects approximately 780,000 Americans
- See a doctor if
- You have persistent diarrhea, abdominal pain, or bloody stools
Symptoms
Causes
- Exact cause unknown; likely an abnormal immune response
- Genetic factors (NOD2/CARD15 and other gene variants)
- Environmental triggers affecting gut microbiome
- Dysregulation of the immune system attacking intestinal tissue
Risk Factors
- Family history of IBD (first-degree relatives at higher risk)
- Smoking (strongest modifiable risk factor—doubles the risk)
- Age between 15 and 35 (peak onset)
- Ashkenazi Jewish heritage
- Use of NSAIDs (may trigger flares)
- Western/industrialized environment
Diagnosis
- Colonoscopy with ileal intubation and biopsies
- CT enterography or MR enterography for small bowel evaluation
- Blood tests (CBC, CRP, ESR) for inflammation markers
- Stool tests (fecal calprotectin) to measure intestinal inflammation
- Capsule endoscopy for small bowel visualization
Treatment
- Aminosalicylates (mesalamine) for mild disease
- Corticosteroids (prednisone, budesonide) for flares
- Immunomodulators (azathioprine, methotrexate) for maintenance
- Biologic therapies (infliximab, adalimumab, vedolizumab, ustekinumab)
- Nutritional therapy and dietary management
- Surgery to remove damaged bowel segments or treat complications
Natural remedies for crohn's disease: what the evidence says
Ranked by the strength of human evidence for crohn's disease specifically. These sit alongside medical care, not in place of it.
Vitamin D
Moderate evidenceLow vitamin D is found in 30 to 60 percent of people with Crohn's, more in active disease and after ileal resection, and low levels track with higher rates of relapse, surgery and hospitalization. In a 12-month placebo-controlled trial of 94 patients in remission, 1,200 IU daily cut relapse from 29 to 13 percent, a difference that just missed statistical significance; a smaller 2017 trial of 34 patients found no relapses on 10,000 IU daily versus 37.5 percent on 1,000 IU. Guidelines recommend checking a vitamin D (25-hydroxy) level and repleting deficiency, chiefly to protect bone in people exposed to steroids.
- Studied dose
- 1,000 to 2,000 IU vitamin D3 daily for maintenance; higher repletion doses guided by a 25-hydroxyvitamin D level, aiming above 30 ng/mL.
- Cautions
- Fat malabsorption makes absorption unpredictable, so recheck the level after about 3 months. Avoid high doses in sarcoidosis, high blood calcium or a history of kidney stones, and tell your clinician if you take a thiazide diuretic, which raises calcium further.
Iron
Moderate evidenceAnemia affects about one in three people with Crohn's and iron deficiency is the leading cause, from blood loss and poor absorption across an inflamed gut. The ECCO anemia guideline defines iron deficiency as a ferritin below 30 ng/mL in quiet disease and below 100 ng/mL when inflammation is active (ferritin rises with CRP), and recommends intravenous iron when disease is active, hemoglobin is under 10 g/dL or oral iron is not tolerated. In the FERGIcor trial (2011, 485 IBD patients), IV ferric carboxymaltose corrected anemia in 66 percent versus 54 percent with iron sucrose. Oral iron works in mild deficiency with inactive disease, but unabsorbed iron feeds inflammation.
- Studied dose
- Oral: up to 100 mg elemental iron once daily or on alternate days when disease is inactive; otherwise IV iron arranged by your clinician.
- Cautions
- Oral iron causes nausea, constipation and dark stools and can worsen Crohn's symptoms. Take it 2 hours apart from levothyroxine, tetracyclines, quinolones and antacids. Ask for a ferritin, iron saturation and hemoglobin before starting rather than guessing.
Vitamin B12
Moderate evidenceB12 is absorbed only in the terminal ileum, the segment Crohn's most often inflames or removes. Deficiency occurs in roughly 20 percent of patients overall and in most people who have had more than 20 cm of ileum resected; beyond 60 cm it is nearly universal. A Cochrane review found high-dose oral B12 (1,000 to 2,000 mcg daily) matches injections when absorption is intact, but after ileal resection injections remain the reliable route.
- Studied dose
- 1,000 mcg by intramuscular injection monthly to every 3 months after ileal resection; 1,000 mcg oral or sublingual daily can be tried when the ileum is intact, with the level rechecked.
- Cautions
- Very safe. Check vitamin B12 yearly, along with folate and the MCV, since a normal MCV does not rule out deficiency in Crohn's. Metformin and proton pump inhibitors lower B12 further.
Zinc
Preliminary evidenceZinc deficiency is reported in about 15 percent of people with Crohn's, driven by diarrhea losses and poor intake. In a 2017 cohort of 773 IBD patients, low zinc predicted more hospitalizations, surgery and complications, and the excess risk disappeared in those whose levels recovered. There is no trial showing zinc prevents flares; this is correction of a deficiency, not a treatment.
- Studied dose
- 25 to 40 mg elemental zinc daily for 8 to 12 weeks when a plasma zinc is low, then recheck.
- Cautions
- More than 40 mg daily for months causes copper deficiency and its own anemia. Separate from quinolone and tetracycline antibiotics by 2 hours; take with food to avoid nausea.
Curcumin
Preliminary evidenceIn a 12-week trial of 30 Japanese adults with mild to moderate Crohn's, 360 mg daily of a high-absorption curcumin (Theracurmin) produced clinical remission in 35 percent versus none on placebo and endoscopic improvement in 40 percent versus none. Against that, a French trial giving 3 g of standard curcumin daily to 62 patients after surgery, alongside azathioprine, found no reduction in postoperative recurrence and was stopped early. Most curcumin evidence in IBD comes from ulcerative colitis and does not transfer to Crohn's.
- Studied dose
- 360 mg Theracurmin daily, or 1 to 3 g daily of a standardized curcumin extract in a phospholipid or piperine formulation; plain turmeric powder is poorly absorbed.
- Cautions
- Mild blood-thinning effect, so caution with warfarin and other anticoagulants. Can cause reflux and loose stools. Piperine-containing products raise blood levels of many drugs, including some immunosuppressants, so tell your gastroenterologist. Avoid with gallstones blocking the bile duct.
Saccharomyces boulardii
Preliminary evidenceAn early 6-month trial in 32 patients found adding S. boulardii 1 g daily to mesalamine cut relapse from 37.5 to 6 percent. The definitive test, a French trial of 165 patients in remission given 1 g daily for 52 weeks, found relapse in 47.5 percent on S. boulardii versus 53 percent on placebo, not a significant difference. It remains the only probiotic with even a hint of benefit in Crohn's; Lactobacillus rhamnosus GG and L. johnsonii failed outright in children and after surgery.
- Studied dose
- 500 mg (about 5 billion CFU) twice daily; the trials used 1 g per day.
- Cautions
- It is a live yeast. Rare bloodstream infections have occurred in people with central venous catheters, severe immunosuppression or critical illness, so ask your clinician before using it on combination immunosuppression. Avoid in yeast allergy; antifungal drugs inactivate it.
What matters day to day
- Stop smoking, with help if you need it: quitting for more than a year brought flare rates down to those of never-smokers in a cohort of 474 smokers with Crohn's, and it halves the chance the disease returns after surgery.
- Swap NSAIDs for acetaminophen: in a study of IBD patients in remission, about one in five relapsed within nine days of starting a conventional NSAID such as ibuprofen or naproxen, while acetaminophen did not trigger flares.
- Learn your calprotectin: a stool calprotectin under 50 mcg/g means the lining is almost certainly quiet, over 250 means active inflammation. Checking it every 3 to 6 months catches a relapse months before symptoms do.
- Eat a Mediterranean pattern built on whole foods: in the DINE-CD trial it matched the far more restrictive Specific Carbohydrate Diet, and in the 116,000-person PURE cohort, people eating five or more servings of ultra-processed food a day had 82 percent higher odds of developing IBD.
- Get vaccinated before starting a biologic or immunomodulator and keep up with flu, COVID-19, pneumococcal and recombinant shingles shots, because infections are the main risk of these drugs; add a yearly skin check if you take a thiopurine or anti-TNF, which raise skin cancer risk.
Prevention
- There is no known way to prevent Crohn's disease
- Quitting smoking significantly reduces risk of flares and disease progression
- Regular medical monitoring can catch complications early
When to See a Doctor
- You have persistent diarrhea, abdominal pain, or bloody stools
- You experience unexplained weight loss or fever
- You develop perianal symptoms (pain, drainage, or swelling)
- Existing Crohn's disease symptoms are worsening despite treatment
Frequently Asked Questions
References
- Lichtenstein GR, Loftus EV, Isaacs KL, et al.. ACG clinical guideline: management of Crohn's disease in adults. American Journal of Gastroenterology (2018)
- Turner D, Ricciuto A, Lewis A, et al.. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD. Gastroenterology (2021)
- Colombel JF, Panaccione R, Bossuyt P, et al.. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet (2017)
- Noor NM, Lee JC, Bond S, et al.. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterology and Hepatology (2024)
- Narula N, Dhillon A, Zhang D, et al.. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews (2018)
- Levine A, Wine E, Assa A, et al.. Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology (2019)
- Lewis JD, Sandler RS, Brotherton C, et al.. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn's disease. Gastroenterology (2021)
- Feagan BG, Sandborn WJ, Mittmann U, et al.. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA (2008)
- Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology (2001)
- Sugimoto K, Ikeya K, Bamba S, et al.. Highly bioavailable curcumin derivative ameliorates Crohn's disease symptoms: a randomized, double-blind, multicenter study. Journal of Crohn's and Colitis (2020)
Related Conditions
Evidence-graded guides
Lab tests that relate to crohn's disease
Related from the Supplement Library
Omega-3 (EPA/DHA)
StrongFatty Acid · Cardiovascular health (TG reduction, anti-arrhythmic)
Vitamin D
StrongVitamin · Bone health and calcium absorption
Probiotics (Lactobacillus)
StrongProbiotic · Gut microbiome balance and diversity
Turmeric
StrongHerb · Reduces systemic inflammation (NF-κB pathway)
L-Glutamine
ModerateAmino Acid · Gut lining repair and intestinal integrity
These supplements have been studied in relation to Crohn's Disease. Always consult your healthcare provider before starting any supplement, especially if you take medications.
Related Reading
Have questions about Crohn's Disease?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.